Cohance Lifesciences has come under investor focus following a recent inspection of its formulation facility in Shamshabad, Telangana, by the US Food and Drug Administration (USFDA).
The inspection was conducted between August 27 and September 4 and concluded with the issuance of a Form FDA 483 containing four observations.
Such observations do not automatically mean that regulatory action will follow, but the company’s response and corrective measures will be closely monitored. Regulatory compliance remains extremely important for pharmaceutical companies with international business exposure
